Healthcare Industry News: TYSABRI
News Release - June 21, 2006
Mark Matthews Joins Javelin Pharmaceuticals as VP of Commercial AffairsWill Prepare Dyloject(TM) Product Launch
CAMBRIDGE, Mass., June 21 (HSMN NewsFeed) -- Javelin Pharmaceuticals, Inc., (OTC Bulletin Board: JVPH ), a leading developer of innovative products for pain control, today announced that Mark Matthews has joined the company as Vice President of Commercial Affairs. Mr. Matthews' initial focus will be to prepare for the successful launch of Javelin's lead product, Dyloject(TM), which is currently under review for marketing approval in Europe and in Phase III clinical development in the U.S. He will also oversee commercial operations and marketing of the company's portfolio of late-stage prescription medications for the treatment of acute moderate-to- severe pain.
Daniel Carr, M.D., Chief Executive Officer of Javelin commented, "We are delighted that Mark has accepted Javelin's commercial leadership role. His record of achievement in the pharmaceutical industry and his familiarity with older formulations of diclofenac are ideal to support Javelin's transition to commercial success."
Prior to joining Javelin, Mr. Matthews was Vice President, Neurology Marketing at Biogen Idec, where he spent several years in charge of the marketing of Avonex® (for multiple sclerosis) and served on the launch team for TYSABRI® (also for multiple sclerosis). Prior to Biogen Idec, Mr. Matthews served as Vice President, Reproductive Health at Serono, and held numerous positions at Novartis (previously Ciba-Geigy and Sandoz). In the latter roles Mr. Matthews gained extensive experience in pain management as Brand Director of Voltaren(TM) and Cataflam(TM), two earlier formulations of diclofenac. Mr. Matthews also has extensive sales and sales management experience having served as a sales representative in his native England and General Manager for Novartis' Northeast Region.
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at http://www.javelinpharmaceuticals.com .
Some of the statements included in this press release, particularly those anticipating future financial performance, clinical and business prospects for our lead drug candidates Dyloject(TM), Rylomine(TM) and PMI-150, growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete cost-effective clinical trials for the drug candidates in our pipelines, including Dyloject(TM), Rylomine(TM) and PMI-150; we may not be able to meet anticipated development timelines for Dyloject(TM), Rylomine(TM) and PMI-150 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.javelinpharmaceuticals.com . The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Source: Javelin Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.